Rapid symptomatic and metabolic response to emergency radiotherapy in a critically ill patient with primary cardiac lymphoma: a multidisciplinary case report Authors: Chengqi Yu, Weiping Liu, Huiming Yu Published: 2026 ABSTRACT Primary cardiac lymphoma (PCL), an exceptionally rare and aggressive malignancy with median survival under one month, often presents with contraindications to first-line chemotherapy in critically ill patients. We report a 66-year-old woman with acute heart failure, pulmonary embolism, and ECOG performance status 4, diagnosed with right atrial diffuse large B-cell lymphoma (76 × 75 mm, SUVmax = 29.1). Due to chemotherapy contraindications, emergency radiotherapy (18 Gy/10 fractions) was initiated. Within five fractions, significant symptomatic improvement occurred with resolution of dyspnea and edema, accompanied by improved oxygenation (SpO₂ 86%→95%) and ECOG status (4→3). Post-treatment PET/CT demonstrated a profound metabolic response (SUVmax = 2.9–3.6), enabling successful transition to systemic chemotherapy. This case underscores emergency radiotherapy as an effective bridge therapy for critically ill PCL patients, facilitated by multidisciplinary coordination. Introduction Primary cardiac lymphoma (PCL) represents less than 2% of primary cardiac malignancies, characterized by rapid progression and dismal prognosis (median survival < 1 month). While immune-chemotherapy remains the cornerstone for systemic disease, critically ill patients with acute cardiac decompensation often face prohibitive treatment risks. The role of radiotherapy in this emergent setting is poorly characterized, with limited evidence detailing its efficacy timeline. We present a paradigm case demonstrating rapid symptomatic and metabolic remission achieved through emergency radiotherapy, highlighting its vital role as a bridge to definitive therapy. Case report A 66-year-old woman presented with two months of progressive chest tightness, dyspnea, and bilateral lower extremity weakness, culminating in acute exertional dyspnea. Clinical evaluation revealed bradycardia (43 bpm), hypoxemia (SpO₂ 86% room air), and a loud cardiac obstructive murmur. Echocardiography and PET/CT identified a 76 × 75 mm right atrial mass with intense FDG avidity (SUVmax = 29.1; Fig. 1). Endomyocardial biopsy confirmed CD20-positive diffuse large B-cell lymphoma (Fig. 2), staged as Ann Arbor IEA (IPI = 3). Although the disease was localized (Ann Arbor Stage IEA), the patient’s age (66 years), elevated LDH, and ECOG performance status 4 resulted in an International Prognostic Index (IPI) score of 3, indicating high-risk features. Acute heart failure and pulmonary embolism rendered her bedbound with ECOG performance status 4. Fig. 1Baseline PETCT demonstrating hypermetabolic right atrial mass (SUVmax = 29.1) Baseline PETCT demonstrating hypermetabolic right atrial mass (SUVmax = 29.1) Fig. 2Histopathology confirming CD20 + diffuse large B-cell lymphoma (H&E) Histopathology confirming CD20 + diffuse large B-cell lymphoma (H&E) A multidisciplinary team initiated cardioprotective measures (diuretics, anticoagulation) but deemed immediate chemotherapy contraindicated. Emergency volumetric-modulated arc therapy (VMAT) was delivered targeting the gross tumor volume with a 0.5 cm margin (18 Gy/10 fractions over five days), prioritizing sparing of coronary arteries and lung parenchyma. Remarkable clinical improvement emerged after five fractions: dyspnea and peripheral edema resolved, oxygen saturation normalized to 95%, and ECOG status improved to 3. Completion PET/CT revealed a near-complete metabolic response with SUVmax reduction to 2.9–3.6, though morphological dimensions remained stable (63 × 24 × 61 mm; Fig. 3). Treatment-related toxicity was limited to moderate nausea (CTCAE v5.0 Grade 2). This response facilitated transition to R-miniCHOP chemotherapy, with sustained tumor control at three-month follow-up. Fig. 3Post-radiotherapy PETCT showing marked metabolic resolution (SUVmax = 2.9–3.6) Post-radiotherapy PETCT showing marked metabolic resolution (SUVmax = 2.9–3.6) Discussion This case provides three novel insights into primary cardiac lymphoma (PCL) management. First, emergency ultra-hypofractionated radiotherapy (18 Gy/10 fractions) achieved clinically meaningful symptom relief within 3–4 days—a time frame rarely documented in PCL. Second, the profound metabolic response (SUVmax reduction from 29.1 to 2.9–3.6, > 90%) preceded morphological regression, confirming FDG-PET as an early surrogate of radiosensitivity. Third, successful transition to R‑miniCHOP after radiotherapy establishes a sequential paradigm for initially chemotherapy‑ineligible patients with acute cardiac decompensation [1]. The symptomatic improvement observed within five fractions warrants mechanistic consideration. Diffuse large B‑cell lymphoma (DLBCL), accounting for approximately 80% of PCL in immunocompetent hosts [2], exhibits rapid apoptosis after DNA damage. In the cardiac setting, mechanical obstruction and inflammatory edema contribute disproportionately to symptoms relative to tumor bulk. Radiotherapy induces early tumor shrinkage through both direct cytotoxicity and microvascular injury, alleviating venous inflow obstruction and improving right ventricular filling more rapidly than chemotherapy [3]. The normalization of SpO₂ (86%→95%) and ECOG improvement (4→3) within days supports this dual mechanism of cytoreduction and decompression. Notably, the “metabolic steal phenomenon”—whereby lymphoma outcompetes healthy myocardium for FDG uptake—has been described in PCL, further underscoring the metabolic aggressiveness of these tumors and the rationale for rapid cytoreductive intervention [4]. The clinical presentation of our patient with bradycardia (43 bpm), hypoxemia, and right atrial mass aligns with the characteristic PCL phenotype, where the right atrium and ventricle are the most frequently involved sites [2, 3, 5]. Nagano et al. previously documented successful treatment of a PCL patient presenting with complete atrioventricular block using combined chemotherapy and radiotherapy, demonstrating that conduction abnormalities can reverse with effective tumor control [6]. The published experience with radiotherapy in PCL consists almost exclusively of consolidative irradiation after chemotherapy. A systematic analysis by Shin et al. demonstrated that combined modality treatment (chemotherapy plus post-chemotherapeutic radiotherapy) achieved superior progression‑free survival compared with chemotherapy alone, with doses ranging from 30 to 40 Gy7. In contrast, our patient received radiotherapy as an emergent bridge rather than consolidation, using a lower dose (18 Gy) to minimize acute cardiac toxicity while achieving sufficient response for subsequent chemotherapy. Crucially, Shin et al. also reported a PCL patient who developed acute myocardial infarction three years after receiving 39.6 Gy cardiac radiotherapy, underscoring the importance of dose optimization when balancing efficacy against long‑term cardiotoxicity [7]. Recent quantitative evidence on cardiac radiation toxicity provides critical context for dose selection in this case. A comprehensive PENTEC meta-analysis involving childhood cancer survivors established precise dose‑response relationships: for each 10‑Gy increase in mean heart dose, the hazard ratio for coronary artery disease is 2.01, for heart failure 1.87, and for valvular disease 1.87, with a linear no‑threshold relationship [8]. Importantly, survivors receiving mean heart dose < 10 Gy at standard fractionation are at low absolute risk (<∼2% at 30 years) in the absence of anthracycline exposure [8, 9]. These findings have direct implications for PCL management. Given the extensive cardiac involvement and the patient’s critical condition with acute heart failure and hemodynamic instability, we deliberately selected a moderate-dose regimen of 18 Gy in 10 fractions (1.8 Gy per fraction) to balance antitumor efficacy with the risk of acute and late cardiac toxicity. This regimen remains within the cardiac dose constraints recommended by the NCCN (mean heart dose < 8 Gy, acceptable up to 15 Gy), and is intentionally lower than standard radical doses (typically 30–40 Gy) used for lymphomas at other anatomical sites, reflecting a risk-adapted strategy in this emergency setting. While this 18 Gy regimen still confers measurable long‑term cardiac risk that must be weighed against the immediate life‑threatening presentation, the VMAT technique with 0.5 cm margins and coronary artery sparing represents a technological advance over earlier two‑dimensional planning that may have contributed to late toxicity in historical series [7]. This approach successfully achieved rapid symptomatic control while maintaining cardiac safety, enabling subsequent transition to definitive chemotherapy. Rapid diagnosis relied on multimodal imaging and timely endomyocardial biopsy, as emphasized in recent PCL literature [7, 10–12]. PET‑CT served as a dynamic biomarker, guiding the decision to proceed with chemotherapy after radiotherapy—a strategy supported by the observation that early metabolic response often precedes morphological changes in PCL [4, 13]. The favorable risk‑benefit balance in this case supports emergency radiotherapy as a bridge to definitive therapy in critically ill PCL patients with contraindications to immediate chemotherapy, while mandating long‑term cardiac surveillance informed by contemporary dose‑response models. Future efforts should focus on optimising radiation dosing strategies that minimise mean heart dose while maintaining efficacy, and exploring synergies with targeted agents in this rare but aggressive malignancy. Conclusion This case demonstrates that emergency radiotherapy can achieve rapid symptomatic and metabolic remission in a critically ill patient with primary cardiac lymphoma, thereby creating a window of opportunity for subsequent systemic therapy. While this outcome suggests that radiotherapy may serve as a potential bridge strategy for patients ineligible for immediate chemotherapy, this observation remains preliminary. The short follow-up period (three months) limits our ability to assess the durability of response and long-term cardiac safety. Further follow-up and additional cases are needed to validate this approach. Limitations Several limitations of this report should be acknowledged. First, and most importantly, the follow-up duration of only three months is insufficient to draw definitive conclusions about the long-term efficacy of this bridging strategy, including the durability of tumor control and the risk of late cardiac toxicity. Second, as a single-case report, the findings are inherently non-generalizable and require validation in larger cohorts or prospective registries. Third, while the observed metabolic response was profound, the stable residual mass on imaging underscores the difficulty in distinguishing between fibrosis and viable tumor without continued surveillance. Finally, although the VMAT technique was employed to minimize cardiac exposure, the potential for long-term radiation-induced cardiac morbidity remains a concern, particularly in the context of subsequent anthracycline-based chemotherapy. Therefore, this case should be viewed as a hypothesis-generating observation that highlights the potential of emergency radiotherapy, rather than definitive evidence of its role.